Navigation Links
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
Date:11/19/2009

nclick="linkClick( this.href );" target="_blank">http://www.ReceptoPharm.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Introducing Nyloxin OTC for international distribution should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

# # #

Read the full story at http://www.prweb.com/releases/Nutra_Pharma/Nyloxin_OTC/prweb3231994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
2. Vivakor Presents at Nutraceutical Event
3. Reportlinker Adds US World Nutraceutical Ingredients Industry
4. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
5. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
6. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
7. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
8. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
9. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
10. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
11. Synutra Annual Report on Form 10-K Includes Going Concern Explanatory Paragraph from Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
(Date:12/24/2014)... December 24, 2014 For nearly 20 ... housewarmings, new babies, graces, and all of life's rites ... and author, Nancy Tupper Ling, in Toasts: The ... Viva Editions. , Organized by category and containing ... won't appear anywhere else, this timely tome contains sayings ...
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, ... might hurt your child in the classroom, a new study ... grade lagged behind by eighth grade, said researchers who reviewed ... "The largest effects were found for the kids who ... Purtell, assistant professor of human sciences at Ohio State University. ...
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/22/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief compliance officer ... Oceanside, Calif. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... Gold Seal-approved, full-service acute-care hospital serving San Diego County’s ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Continued year over year growth driven by Loestrin 24 and Taclonex; ... updates full year 2007 financial guidance, ... ) today announced its results for the quarter ended,September 30, 2007. ... increase of 16.3%, over the prior year quarter. The,primary drivers of ...
... announced today that the U.S. Food and Drug ... adjunct to diet to slow,the progression of atherosclerosis ... CRESTOR an important differentiator from,competitors in the cholesterol-lowering ... share what we,ve learned in clinical,trials -- that ...
... EXTON, Pa. and SAN DIEGO, Nov. 9 ,RS&A, ... of oncology equipment sales and service, announced today ... Radiology Oncology Systems, Inc.,(ROS), an oncology and diagnostic ... a US provider of oncology equipment service,and distributor ...
... 8 State,Compensation Insurance Fund is presenting a ... Fund,s Employer Education Series, featuring its own,innovative and ... seminar entitled "Watch Your Back",introduces an educational and ... the very people they are trying to protect ...
... following release is,being issued by the Department of ... is the largest federal provider of direct assistance ... and case,management, employment, rehabilitation, transitional residential care,therapeutic work ... has been a 22 percent reduction in the ...
... Warns of Critical and Fatal Implications of ... the Diagnosis of Carbon Monoxide Poisoning, IRVINE, Calif., ... Read-Through Motion and Low Perfusion pulse,oximetry, today announced the ... all its members advocating carbon monoxide,screenings for patients presenting ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 2Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 3Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 4Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3Health News:Homeless Vets - VA Sets the Record Straight 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 3
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... SPRINT-1 study presented at AASLD annual meeting, ... patients and those,who failed prior treatment, SAN ... ) today reported that a planned interim analysis ... investigational oral hepatitis C,protease inhibitor, in combination with ...
... COPENHAGEN, Denmark, October 31 , - DoctorConsult ... That Improve Clinician Decision Making and Health Care ... workflow and more than a,century of experience as ... to provide interactive clinical reference and clinical decision,support ...
Cached Medicine Technology:Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
... For use in the percutaneous retrieval of indwelling ... wire guides, and other foreign objects. A ... around the lead body. It is delivered to ... flexible 12 Fr cannula that is placed coaxially ...
... Novalis, BrainLAB's dedicated ... radiosurgery and radiotherapy (SRS/SRT), ... highly precise treatments of ... head & neck tumors, ...
The Radionics XKnife RT2 system provides a precise and versatile stereotactic radiation therapy solution....
Clinac EX Platinum accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: